All Search Results
News Releases
May 14, 2026, 08:10 ET CREATE Medicines Strengthens Clinical and Scientific Advisory Board with Appointment of Georg Schett, MD, Margrit Wiesendanger, MD, PhD, and Christopher Jewell, PhD
University of Wisconsin. He is a member of the PhRMA Advisory Committee and has served on White House OSTP committees.About CREATE MedicinesCREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly
More news about: CREATE Medicines, Inc.
May 14, 2026, 08:00 ET CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline in Autoimmune Disease and Oncology
programming capabilities position it to play an important role in the future of autoimmune disease and oncology."About CREATE MedicinesCREATE Medicines is a clinical-stage biotechnology company pioneering in vivo immune programming. The company's proprietary mRNA-LNP platform directly
More news about: CREATE Medicines, Inc.
Apr 23, 2026, 08:02 ET CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors
offer a new therapeutic paradigm that may overcome resistance patterns and deliver more sustained disease control.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Apr 17, 2026, 11:00 ET CREATE Medicines to Showcase Multi-immune In Vivo CAR T, CAR NK, and All-RNA RetroT Platform at AACR 2026
#: 20Abstract #: LB155More information is available on the AACR Annual Meeting website.About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
Feb 02, 2026, 16:00 ET CREATE Medicines Demonstrates Complete B Cell Depletion and Repeatable Dosing in Non-human Primates with In Vivo CAR-T Platform
https://www.keystonesymposia.org/conferences/conference-listing/meeting/onpage-program/K22026About CREATE MedicinesCREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside
More news about: CREATE Medicines, Inc.
